Deciphera Pharmaceuticals, Inc. to Announce Third Quarter 2019 Financial Results & Host Conference Call & Webcast on November...
October 28 2019 - 7:00AM
Business Wire
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a clinical-stage
biopharmaceutical company focused on addressing key mechanisms of
tumor drug resistance, today announced that it will report its
third quarter 2019 financial results on Monday, November 4,
2019.
In connection with the earnings release, Deciphera’s management
team will host a live conference call and webcast at 4:30 PM ET on
Monday, November 4, 2019, to discuss the Company’s financial
results and provide a general corporate update.
The conference call may be accessed by dialing (866) 930-5479
(domestic) or (409) 216-0603 (international) and referring to
conference ID 1181263. A webcast of the conference call will be
available in the “Events and Presentations” page in the “Investors”
section of the Company’s website at
https://investors.deciphera.com/news-events/events-presentations.
The archived webcast will be available on the Company's website
approximately two hours after the conference call and will be
available for 30 days following the call.
About Deciphera Pharmaceuticals
Deciphera Pharmaceuticals is a clinical-stage biopharmaceutical
company focused on improving the lives of cancer patients by
addressing key mechanisms of drug resistance that limit the rate
and/or durability of response to existing cancer therapies. Our
small molecule drug candidates are directed against an important
family of enzymes called kinases, known to be directly involved in
the growth and spread of many cancers. We use our deep
understanding of kinase biology together with a proprietary
chemistry library to purposefully design compounds that maintain
kinases in a “switched off” or inactivated conformation. These
investigational therapies comprise tumor-targeted agents designed
to address therapeutic resistance causing mutations and
immuno-targeted agents designed to control the activation of
immunokinases that suppress critical immune system regulators, such
as macrophages. We have used our platform to develop a diverse
pipeline of tumor-targeted and immuno-targeted drug candidates
designed to improve outcomes for patients with cancer by improving
the quality, rate and/or durability of their responses to
treatment.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20191028005262/en/
Investor Relations: Jen Robinson Deciphera Pharmaceuticals, Inc.
jrobinson@deciphera.com 781-906-1112
Media: David Rosen Argot Partners David.Rosen@argotpartners.com
212-600-1902
Deciphera Pharmaceuticals (NASDAQ:DCPH)
Historical Stock Chart
From Mar 2024 to Apr 2024
Deciphera Pharmaceuticals (NASDAQ:DCPH)
Historical Stock Chart
From Apr 2023 to Apr 2024